Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

SHY trades at $81.96, showing minimal daily movement with a slight decline of 0.04%. The technical outlook is mixed with a bullish overall signal but bearish moving averages, while key support and resistance cluster around $82. Recent corporate actions include consistent dividend payments of $0.24, with the latest scheduled for July 2026. Financial ratios are not disclosed in the provided data, limiting fundamental visibility.

The outlook for SHY is clouded by incomplete financial data, though steady dividends provide income appeal. Key risks include interest rate sensitivity amid Federal Reserve uncertainty, as bond market volatility could impact performance. Investors should seek updated SEC filings for fundamental clarity before considering positions.